THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era. Wednesday, March 25, 2026

COMPOUND WATCH

Orforglipron (Lilly, oral GLP-1 RA) [Phase 3] ACHIEVE-3 data dropped in The Lancet today — 1,698 T2D participants, 52 weeks, four arms. Orforglipron at 12mg and 36mg beat oral semaglutide at 7mg and 14mg on every primary and key secondary endpoint: A1C, weight loss, non-HDL, HDL, VLDL, total cholesterol, systolic BP. The practical differentiator: no food or water timing restrictions. Oral semaglutide requires a 30-minute fasted window with minimal water. Orforglipron: take it whenever.

The number that determines whether you'd actually stay on it: discontinuation due to adverse events ran 8.7% (12mg) and 9.7% (36mg) for orforglipron vs. 4.5% and 4.9% for oral semaglutide — roughly double the dropout rate. GI profile consistent with prior trials: nausea, diarrhea, vomiting, dyspepsia. Weight loss in the T2D population: 6–8% at 52 weeks — meaningful, but well below tirzepatide's ~20–22% at 72 weeks in the obesity population. FDA obesity decision: April 10. Lilly has $1.5B in pre-launch inventory staged. The approval itself isn't the signal — the pricing announcement within 24 hours is. Above ~$400/month self-pay = compounding demand for injectable tirzepatide/semaglutide stays intact. Below ~$300/month = watch for patient migration to oral and compounder capacity reallocation.

Tirzepatide [Phase 3] Two new data points. First: a real-world CV study in Diabetes Care (Ostrominski et al., Brigham & Women's/Harvard, Optum Clinformatics). Tirzepatide vs. dulaglutide (n=9,233 dulaglutide arm, median follow-up 4.9 months): 20% lower risk for major adverse CV events, all-cause mortality HR=0.70 (95% CI 0.55–0.90). Tirzepatide vs. semaglutide (n=25,266 per arm, median follow-up 7.1 months): no statistically significant CV difference — the two are equivalent at this follow-up length. Note the 7.1-month follow-up is shorter than dedicated CV outcome trials; treat "equivalent" as provisional, not definitive. Clinical read: both tirzepatide and semaglutide beat dulaglutide on CV outcomes. Neither has yet beaten the other in a powered CV outcomes trial.

Second: a meta-analysis in Respiratory Medicine (Yang et al., 10 trials, 1,280 patients). Tirzepatide reduced AHI by −21.85 events/hour (95% CI −27.52 to −16.34) vs. −5.19 for GLP-1 RAs broadly and −7.73 for SGLT-2 inhibitors. Context that makes this number land: moderate OSA is defined as 15–30 events/hour; severe is 30+. A −21.85 reduction from a severe baseline (say, 35 events/hour) pushes most patients below the moderate threshold. That's not just statistically significant — that's clinically meaningful. Mechanism is likely weight loss, not direct airway effect. Tirzepatide also drove −19.41 kg body weight in this population.

Tirzepatide + Menopausal Hormone Therapy [Phase 2 / Retrospective] Mayo Clinic retrospective (n=120, ≥12 months tirzepatide): postmenopausal women on MHT lost 35% more weight than those on tirzepatide alone. Similar baselines between groups. Preclinical data suggest estrogen may potentiate GLP-1 appetite suppression. Randomized trial planned. This is a retrospective — confounding is possible — but the signal is large enough to track. If you're a postmenopausal woman on tirzepatide and not on MHT, this is worth raising with your prescriber before the RCT data arrives.

Semaglutide — Alzheimer's [Phase 3 — FAILED] Evoke and Evoke+ results published in The Lancet (Cummings et al., DOI: 10.1016/S0140-6736(26)00459-9). Two large RCTs, 566 sites, 40 countries, 1,600+ participants aged 55–85. Oral semaglutide up to 14mg vs. placebo over 156 weeks. Primary endpoint (CDR-SB score change): no statistically significant difference. No improvement in secondary endpoints or Alzheimer's biomarkers. Novo stopped both trials in November 2025 — this is the formal publication. Leading hypothesis for failure: oral bioavailability may be insufficient for CNS penetration. Injectable semaglutide is still under separate investigation. If you were dosing oral semaglutide off-label for cognitive protection, this data removes the justification.

GLP-1 Discontinuation — The Weight-Regain Narrative Is Wrong [Real-World Data] This finding deserves more than a bullet. Cleveland Clinic real-world data (~8,000 adults prescribed semaglutide or tirzepatide for 3–12 months before stopping): average weight loss before stopping was 8.4%; one year after stopping, only 0.5% regained on average. 19.6% restarted their original medication; 14% switched to an alternative obesity treatment. This directly challenges the "you'll regain everything" narrative that drives a lot of continuous-use decisions — and the fear-based marketing around GLP-1 discontinuation. The caveat: this is a 3–12 month treatment window, not the multi-year users. Patients who remained engaged with healthcare maintained weight loss better. The broader discontinuation problem remains real: 46.5% of T2D patients and 35.5% of non-T2D patients discontinue GLP-1 medications within 1 year (6-year study, 125,000+ patients) — but the "regain everything immediately" framing isn't supported by this data.

BPC-157 [Animal / Zero Human RCTs] Still zero published human RCTs. See TRIAL TRACKER for the one development that changes the trajectory.

VENDOR SIGNAL

No new Finnrick rating changes, failed HPLC results, or Janoshik test disclosures in today's data. No FDA warning letters against named peptide vendors or compounding pharmacies today — the most recent enforcement context remains the 30 warning letters to telehealth companies over compounded GLP-1 products and the GenoGenix bacterial endotoxin contamination case.

Vendor grade key (for new readers): [Verified] = Finnrick-tested, 98%+ purity confirmed by independent HPLC. [COA Only] = vendor provides manufacturer certificate of analysis but no independent third-party HPLC verification. [Unverified] = no COA, community reports only. [Flagged] = failed independent testing, FDA warning letter, or multiple community complaints.

[COA Only] — The absence of new verified test data is not reassurance. The 15–20% COA discrepancy rate on independently tested peptides is a standing baseline, not a resolved problem. If you're sourcing BPC-157, TB-500, or CJC-1295 from a research chemical vendor and the last independent HPLC test on that batch is more than 60 days old, treat it as unverified.

[Unverified] — Gray-market vendors (QSC, SRY, GYC and equivalents) have no new quality data today. No customs seizures reported, no warehouse status changes. Operationally stable as of today — but see THE ODDS for the tariff cost-basis signal.

Compounding pharmacy channel: 503B facilities are at 72 registered nationally, down from approximately 90+ in 2023 when the Category 2 list was established — a ~20% contraction in three years. If your compounder is a 503A (patient-specific), they are operating under enforcement discretion for Category 2 peptides, not formal legal authorization. The RFK reclassification promise has not changed that legal status as of today.

Check finnrick.com for current vendor ratings before your next order.

TRIAL TRACKER

BPC-157 — Phase 2 Hamstring Strain [NCT07437547] [Phase 2] Recruiting since February 2, 2026. This is the first registered controlled human trial in BPC-157's history — it ends the "zero human data" era and creates a formal evidence pathway. Phase 2 is safety and dosing, not efficacy proof, so it doesn't validate the compound. But if safety data reads out clean, it materially changes the risk calculus for the hundreds of thousands of people already injecting it. Decision gap addressed: The trial site list and enrollment criteria are not yet published in available data — ClinicalTrials.gov [NCT07437547] is the place to check eligibility directly. If you're a regular BPC-157 user with a recent hamstring strain, check the site list before your next order, not after.

Retatrutide — Phase 3 Obesity [NCT07357415, NCT07232719] [Phase 3] Lilly's triple agonist (GIP/GLP-1/glucagon) now has two additional Phase 3 obesity trials recruiting (January and November 2025 starts), alongside the chronic low back pain trial (NCT07035093, recruiting since May 2025) and the TRIUMPH-Outcomes CV/kidney trial (NCT06383390, active). Phase 2 showed ~24% body weight loss at 48 weeks — the highest number in the GLP-1 class to date. If Phase 3 confirms, tirzepatide's 22.5% becomes second place. No compounded version exists yet. Watch for gray-market API sourcing to emerge as Phase 3 data matures — that's typically a 12–18 month lead time from Phase 3 enrollment to community availability.

Survodutide — Phase 3 MASH [NCT06632444, NCT06632457] [Phase 3] Boehringer Ingelheim's GLP-1/glucagon dual agonist has two active Phase 3 MASH trials (LIVERAGE and LIVERAGE-Cirrhosis). The glucagon component differentiates it from pure GLP-1 agonists on hepatic fat reduction. Not yet on most biohackers' radar — but MASH is the next major indication battleground after obesity and CV. If Phase 3 reads positive, expect compounding interest to spike. File as a 12–18 month watch.

THE ODDS

SIGNAL 1: China Tariffs — 25% import duty, gray-market peptide costs up 15–30% No Polymarket market tracks this directly, but the macro trade war context is live and unchanged. A sustained 25% tariff on Chinese goods raises your landed cost for gray-market peptides 15–30% by the time it reaches a U.S. reshipping address — not at the factory gate, but through the import and domestic fulfillment chain. If you're ordering from QSC or SRY, factor this into your cost basis now. No new customs seizure data today, but the structural risk is unchanged. The "tariff dividend" Polymarket market (1% probability by March 31) is effectively closed — the tariff relief trade is dead. The tariffs are the baseline.

SIGNAL 2: Inflation at 98% probability — $206K volume Polymarket has inflation above 3% in 2026 at 98% — priced as a near-certainty by real money. For your monthly bill: compounding pharmacy overhead (labor, materials, regulatory compliance) rises with inflation, and those costs flow directly into pricing. The $200–500/month compounded tirzepatide range has held for 18 months. At sustained 3%+ inflation with 72 remaining 503B facilities competing for shrinking margins, expect the floor to drift upward in Q3. Gray-market Chinese-sourced peptides are partially insulated — API pricing is dollar-denominated at the factory level — but domestic fulfillment and testing costs are not.

SIGNAL 3: Recession at 34% — $855K volume Below the threshold where behavioral change kicks in — as a rule of thumb, discretionary health spending starts softening above ~40% recession odds (based on historical consumer spending patterns in prior downturns, not a formal model). At 34%, the gray-market channel actually benefits slightly: people who can't afford $900/month brand Ozempic but won't give up GLP-1s migrate toward compounders and research chemical vendors. If odds cross 40%, watch for increased QSC/SRY order volume and compounder price sensitivity. Not there yet.

SIGNAL 4: No Fed rate cuts in 2026 at 29% — $2.45M volume The high-volume signal. If rates stay elevated (71% chance of at least one cut, but 29% chance of none), the telehealth-to-compounding pipeline stays under financial pressure. The Hims-Novo deal's economics — and whether it becomes a template other telehealth platforms follow — depends partly on rate trajectory. A no-cut 2026 tightens telehealth margin structures and may accelerate the shift toward authorized distributor models over compounding.

April 10 is the most binary date on the peptide market calendar right now. Know the efficacy data before the pricing announcement drops — because the pricing number, not the approval itself, determines whether your compounder's phone starts ringing or goes quiet.

SIGNAL VS. NOISE

SIGNAL: Orforglipron ACHIEVE-3 Lancet data — beats oral semaglutide on all endpoints 1,698 participants, 52 weeks, peer-reviewed Phase 3. This is real. The no-timing-restriction advantage is a genuine differentiator for adherence. The higher discontinuation rate (roughly 2x oral sema) is a real limitation. FDA decision April 10. If approved and priced accessibly, this is the compound that accelerates oral GLP-1 adoption — and potentially reduces compounding demand for injectable semaglutide/tirzepatide among patients who were injecting primarily for convenience.

SIGNAL: BPC-157 Phase 2 trial now recruiting [NCT07437547] First registered controlled human trial in BPC-157's history. Doesn't validate the compound — but ends the "no human data" era. Check ClinicalTrials.gov for enrollment criteria before your next order if you have an active hamstring injury.

SIGNAL: Semaglutide Alzheimer's Phase 3 failure — published, not just announced Evoke/Evoke+ is now in The Lancet with full methodology. Definitive for oral semaglutide in mild AD/MCI over 156 weeks. Injectable semaglutide still under separate investigation — this doesn't close the GLP-1/neurodegeneration hypothesis. But oral semaglutide off-label for cognitive protection no longer has a data justification.

SIGNAL: Cleveland Clinic weight-regain data challenges continuous-use fear narrative Only 0.5% average weight regained one year after stopping — not the "regain everything" story. This is real-world data from ~8,000 patients. It doesn't mean stopping is optimal, but it does mean the fear-based framing driving some continuous-use decisions isn't supported by this dataset.

NOISE: RFK Jr. "14 peptides unbanned within weeks" — February podcast, still no action The "within a couple of weeks" window from February has passed. No Federal Register notice. No formal FDA announcement. No named compound has been reclassified. The AInvest article framing this as an "imminent regulatory catalyst" is AI-generated content citing a podcast comment. Treat your current sourcing decisions as if the Category 2 list is unchanged, because legally it is.

NOISE: India generic semaglutide at $23/month as a US sourcing option Zydus launched injectable semaglutide at ~₹2,200/month (~$23.40 USD). Torrent launched oral semaglutide generic "Sembolic" at ₹149/tablet (~$1.59 USD) — the more provocative number for anyone thinking about gray-market oral access. Neither has a legal US import pathway. The DCGI simultaneously launched a crackdown — 49 entities audited. Customs seizure risk is high. The price floor is real; the access pathway for US consumers is not.

NOISE: Tirzepatide + MHT = 35% more weight loss Interesting and worth tracking — but it's a retrospective study of 120 patients, not a randomized trial. Confounding is possible. Randomized trial planned. File under "promising signal, not actionable protocol change yet."

REGULATORY RADAR

RFK Jr. Peptide Reclassification — Promise vs. Reality RFK Jr. said on a February podcast that the FDA plans to lift restrictions on 14 of 19 Category 2 peptides "within weeks." Named compounds in the 2023 ban include BPC-157 and CJC-1295. As of today — March 25, 2026 — no Federal Register notice, no formal FDA announcement, no HHS press release, and no named compound has been reclassified. The "within weeks" timeline has elapsed.

What this means operationally: your 503A compounder is still operating under enforcement discretion, not formal authorization, for Category 2 compounds. That discretion can be withdrawn. The 503B channel (72 facilities, down ~20% from 2023) is the only formally compliant compounding pathway — and most 503B facilities are not producing research peptides.

What would change the calculus: A Federal Register notice proposing reclassification, or a formal FDA guidance document. Neither exists today. Set a Google Alert for "Federal Register peptide reclassification" and ignore everything else until that notice appears. Another podcast comment is not the signal.

Hims-Novo Deal — No New Developments Today The deal structure (Hims to offer branded Ozempic + Wegovy injectable and tablet; Hims stops advertising compounded GLP-1s) is unchanged. The template of telehealth-as-authorized-distributor rather than telehealth-as-compounder is the structural shift to watch — but it's not moving today. No fresh data.

WHAT TO WATCH

April 10 — Orforglipron FDA obesity decision. Binary event. Approval is likely priced in. The pricing announcement within 24 hours is the actual signal. Above ~$400/month self-pay = compounding demand for injectable tirzepatide/semaglutide intact. Below ~$300/month = watch for patient migration to oral and compounder capacity reallocation. Know the efficacy data now so you're not reading the label when the price drops.

Now — BPC-157 Phase 2 trial [NCT07437547]. If you have an active hamstring strain and are a regular BPC-157 user, check enrollment eligibility at ClinicalTrials.gov before your next order. Trial site list not yet in available data — the registry is the primary source. This is the first formal human evidence pathway for the compound; enrollment matters.

Ongoing — RFK reclassification. The signal to watch for is a Federal Register notice, not another podcast. Until that notice appears, the Category 2 list is operationally unchanged.

Thursday, March 26. Check Finnrick for any vendor rating updates — no changes today, but the site updates independently of this newsletter. If you're reconstituting a new BPC-157 batch this week, verify the batch number against the most current independent test data before injecting.

Numbers that matter: - 600,000+ prescriptions written for Novo's oral Wegovy pill since January 2026; >1/3 of users are new to GLP-1 drugs entirely (Truveta data) - 11% of American adults currently on a GLP-1 prescription (Leger Healthcare survey, March 2026, n=1,012 Americans) - Wegovy HD (7.2mg) approved — 20.7% average body weight loss vs. Zepbound's 22.5% — Novo closes the gap but doesn't close it - Novo Nordisk stock: ~$36.89, near 52-week low of $35.85, P/E ~10x; down 28% YTD - Lilly stock: ~$902–914, down ~13% YTD despite Mounjaro + Zepbound delivering >$11B last quarter - Oral GLP-1 market projected at $40–45B annually by 2030; Goldman Sachs sees oral capturing 24% of total GLP-1 market by 2030; Novo projects >33% of its own GLP-1 mix - Oral insulin DNP peptide (Kumamoto University, preclinical): cyclic DNP peptide platform achieves ~33–41% bioavailability vs. subcutaneous injection — historically oral insulin required ~10x the dose to match injectable. Two delivery strategies: interaction-based mixing and covalent conjugation via click chemistry. Preclinical stage, further animal trials needed. Relevant to anyone thinking about oral peptide delivery mechanisms — including whether oral BPC-157 formulations have any scientific basis. [Animal / In Vitro] - Torrent Sembolic (India oral semaglutide generic): ₹149/tablet (~$1.59 USD). No legal US import pathway. This is the price floor the global market is moving toward — not an actionable sourcing option for US consumers today, but the number that explains why brand GLP-1 pricing is structurally unsustainable long-term.

Reply to this email with feedback — what's useful, what's missing, what you want more of.

Stay curious, stay skeptical. — The Dose

Like what you're reading? Upgrade to Premium for early-access signals, weekly deep-dives, and the full 12-month archive. Founding members: $15/month. Manage your subscription.